Umut Meriç – General Manager, Chiesi Turkey
Two months into the role, Umut Meriç, general manager for Chiesi Turkey, discusses the affiliate’s rapid progression and his plans to ensure Turkish patients benefit from the global company’s latest…
Chiesi, founded in 1935, serves patients in 60 countries, with a total turnover of EUR 1.3 billion per year, in the areas of respiratory disease, neonatal intensive care, allergy, and cardiology. R&D efforts are currently targeting conditions such as cystic fibrosis, organ transplantation, and rare diseases, with approximately 20 percent of annual turnover invested in R&D each year. Chiesi Turkey was founded in 2007, and has grown quickly to become the 50th ranked pharmaceutical company in the market.
Contact Details
Büyükdere Cad. No: 122 Özsezen Business Centre Block C Floor: 3
Esentepe – Sisli 34394 Istanbul / Turkey
Tel: 0212 370 91 00 –
Fax: 0212 370 91 27
info.tr@chiesi.co I
Two months into the role, Umut Meriç, general manager for Chiesi Turkey, discusses the affiliate’s rapid progression and his plans to ensure Turkish patients benefit from the global company’s latest…
Turkey is quickly becoming a regional hub for pharmaceutical industry for management, clinical trials and manufacturing, explains the general manager of Chiesi Turkey. How important is it for the government…
Keyman’s general manager discusses his firm’s development efforts towards vaccine production, in conjunction with TUBITAK and Hacettepe University, and their geographic expansion into Africa, Latin America, and Southeast Asia. Please…
A recent arrival from China, Lilly’s Turkey MD Daniel Lucas assesses the country’s healthcare system and raises key questions about the sustainability of the system at large going forward, and…
MSD Turkey has benefited in recent years from the ability to engage in local business development initiatives, and managing director Hatice Demiray has prioritized initiatives such as reducing internal bureaucracy…
GSK’s VP and Area GM Pharmaceuticals, Turkey and Caucasus, and chairman of Turkey’s innovative pharmaceutical association, discusses the effectiveness of the government’s current strategy for reducing the trade deficit in…
Imuneks is currently operating in the OTC market, but with three supergeneric products ready to market on the RX side, the firm has the potential to soon become one of…
Recordati’s South East regional VP, based in Istanbul, discusses Recordati Turkey’s key role as a manufacturing hub for Recordati, the importance of the Turkish market (fourth largest globally for the…
Turkey is quickly becoming a regional hub for pharmaceutical industry for management, clinical trials and manufacturing, explains the general manager of Chiesi Turkey. How important is it for the government…
Biocodex’s new general manager gives an overview of the affiliates ‘new deal’ program, and how the company has adjusted its approach to better fit the contemporary Turkish environment. What attracted…
The general manager of Daiichi Sankyo Turkey discusses his affiliate’s expansion into a regional hub, current strategies for growth in the Turkish market, and the keys behind his affiliates multiple ‘great…
Turkey’s leading pharmaceutical company is in the process of developing production facilities abroad, and it has just begun construction of a USD 100 million biotech facility; CEO Süha Taşpolatoğlu believes…
The leadership of Turkey’s newest major pharmaceutical player, Pharmactive, discuss the firm’s two pronged growth strategy, detailing their own sales objectives and prospects, as well as the opportunities that they…
Polifarma is Turkey’s largest producer of basic parenteral IV solutions with a 41 percent market share the country and growing exports across the region. According to the Chairman and CEO…
See our Cookie Privacy Policy Here